Astrazeneca (AZN) FCF Margin (2009 - 2026)

Astrazeneca's FCF Margin history runs 17 years deep, the most recent figure standing at 710.39% for Q1 2026.

• In Q1 2026, FCF Margin rose 13066.0% year-over-year to 710.39%; the TTM figure through Mar 2026 stood at 2639.22% (down 243838.0% YoY), while the FY2025 annual figure was 27.11%, down 148968.0% from the prior year.
• FCF Margin was 710.39% for Q1 2026 at Astrazeneca, up from 76400.0% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 9550.0% in Q2 2024 to a low of 76400.0% in Q4 2025.
• Historically, FCF Margin has averaged 3097.3% across 5 years, with a median of 710.39% in 2026.
• The sharpest annual moves came in 2024 and 2025: FCF Margin jumped 941010 bps in 2024, then sank 7601472 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 8433.33% in 2022, then slumped by 98 bps to 139.9% in 2023, then tumbled by 375 bps to 385.28% in 2024, then tumbled by 19730 bps to 76400.0% in 2025, then jumped by 101 bps to 710.39% in 2026.
• The last three FCF Margin figures came in at 710.39% (Q1 2026), 76400.0% (Q4 2025), and 6236.36% (Q3 2025), per Business Quant data.